MLTX INVESTMENT: MoonLake Immunotherapeutics Investors with Losses may have Rights in Securities Class Action – Contact BFA Law by December 15 Deadline

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically targeting moderate to severe hidradenitis suppurativa with its investigational drug sonelokimab [3]. Group 3: Clinical Trials and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients, suggesting a competitive advantage for sonelokimab [4]. - Allegations state that the clinical data and Nanobody structure did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].